Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk

by Jason E. Michaud, Kevin L. Billups, Alan W. Partin
Published 2015-12-01

Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [18F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation

by Eugene Shenderov, Michael A. Gorin, Seohyun Kim, Pamela T. Johnson, Mohamad E. Allaf, Alan W. Partin, Martin G. Pomper, Emmanuel S. Antonarakis, Kenneth J. Pienta, Steven P. Rowe
Published 2018-03-01

In Reply

by W. Nathaniel Brennen, Michael T. Schweizer, Hao Wang, Trinity J. Bivalacqua, Alan W. Partin, Su Jin Lim, Carolyn Chapman, Rehab Abdallah, Oren Levy, Neil A. Bhowmick, Jeffrey M. Karp, Angelo De Marzo, John T. Isaacs, Samuel R. Denmeade
Published 2019-07-01

Clinical Validation of the 2005 ISUP Gleason Grading System in a Cohort of Intermediate and High Risk Men Undergoing Radical Prostatectomy.

by Sheila F Faraj, Stephania M Bezerra, Kasra Yousefi, Helen Fedor, Stephanie Glavaris, Misop Han, Alan W Partin, Elizabeth Humphreys, Jeffrey Tosoian, Michael H Johnson, Elai Davicioni, Bruce J Trock, Edward M Schaeffer, Ashley E Ross, George J Netto
Published 2016-01-01

Feasibility of integrating canine olfaction with chemical and microbial profiling of urine to detect lethal prostate cancer.

by Claire Guest, Rob Harris, Karen S Sfanos, Eva Shrestha, Alan W Partin, Bruce Trock, Leslie Mangold, Rebecca Bader, Adam Kozak, Scott Mclean, Jonathan Simons, Howard Soule, Thomas Johnson, Wen-Yee Lee, Qin Gao, Sophie Aziz, Patritsia Maria Stathatou, Stephen Thaler, Simmie Foster, Andreas Mershin
Published 2021-01-01